Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Oncology Practice Insider

ASCO’s Oncology Practice Insider provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high quality patient care. OPI offers updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. To sign up for the biweekly Oncology Practice Insider newsletter, please complete this form.

The Georgia Society of Clinical Oncology successfully worked to move two important PBM bills through the Georgia legislature. Read more about their advocacy efforts and how you can work with your state society to affect policy on behalf of your patients and practices. “We felt that if we were able to get this legislature to pass bill, then other states would be able to use it as a model,” Dr. Melissa Dillmon said. Read more in the ASCO Daily News.
On August 2, 2019, the Food and Drug Administration approved pexidartinib (TURALIO™, Daiichi Sankyo) capsules for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. Pexidartinib is the first systemic therapy approved for patients with TGCT. Read more.
The first practice outside of the U.S. to achieve Quality Oncology Practice Initiative (QOPI®) Certification is now the first to be re-certified.
ASCO has released an ethical framework for researchers on incorporating research biopsies in cancer clinical trials in the Journal of Clinical Oncology. The framework provides guidance on when to include optional and mandatory biopsies based on both participant risk and scientific utility, as well as recommendations on necessary steps for improving the conduct of research biopsies overall. Learn more.
ASCO is currently soliciting applications for two funding opportunities, both aimed at supporting practices’ participation in three of ASCO’s quality initiatives: the Quality Oncology Practice Initiative (QOPI®), QOPI Certification Program, and Quality Training Program. Susan G. Komen®
On July 30, 2019, the Food and Drug Administration approved darolutamide (NUBEQA®, Bayer HealthCare Pharmaceuticals Inc.) for non-metastatic castration-resistant prostate cancer. Read more.
ASCO’s online community platform, myConnection, provides ASCO members with the opportunity to connect, collaborate, participate in in-depth discussions, and receive feedback and resources with the nearly 45,000 members in ASCO’s global network. We know the value ASCO members put on networking and collaboration, and we are excited to provide ASCO members with an environment to connect and engage in real time.
This year’s meeting will take place on September 22-23, 2019, at ASCO’s headquarters in the Washington, DC metro area. Highlights include a FDA Audit Readiness Workshop and a Keynote Address from FDA Oncology Center of Excellence Director, Richard Pazdur, MD. Register and Save Now!